Merck Schering-Plough

Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial. Press Release. January 14, 2008. http./Avww. merck.com/newsroom/press—releases/product/2008-0125.html... 

Flores NA. Ezetimibe + simvastatin (Merck/Schering-Plough). Curr Opin Investig Drugs 2004 Sep 5(9) 984-992. 

Companies with one blockbuster brand or R D budget of > 1 billion are listed. Marketing joint ventures like Takeda-Abbott Pharmaceutical, Merck-Schering Plough are not listed. 

Several non-peptide small molecule compoimds from Merck, Schering-Plough, Bristol-Myers Squibb, and Janssen are in phase I clinical trials for the treatment of cancer. This has bolstered the significance of this approach of cancer chemotherapy. Other organizations that have ongoing active FPTase inhibitor programs include Abbott, Rhone Poulenc Rorer, Parke- Davis, Pfizer, Zeneca, Eisai and Biomeasure. While several review articles have recently been published that cover various aspects of FPTase inhibitors [25-28,31,60,61], the discussion of FPTase inhibitors derived from natural products is limited. Therefore, this article will not be an extensive review of the literature dealing with chemically derived inhibitors of farnesyl-protein transferase. Rather, it will focus on inhibitors of famesyl-protein transferase that have been identified from natural product sources discovered by Merck or other institutions. 

SHARP Rory Collins Collin Baigent (Oxford) Merck/ Schering Plough Statin on CV and renal progression Ezetimile Not only diabetes ... 

Financial resources for the colloquium were provided by the Academy and supplemented by contributions from a number of industries (American Cyana-mid Company, E. I. DuPont de Nemours Co., Givaudan-Roure Corporation, Merck Co., Monsanto, Rohm and Haas Company, Schering-Plough Research Institute, Sterling-Winthrop Inc., Syntex, Takasago International Corporation, Zeneca Inc.), to which we are much indebted. 

June 19 Four companies, Johnson Johnson, Pfizer, Merck, and Schering-Plough, agree to a six-month moratorium on advertising of new drugs and to modify payment of celebrities and experts who endorse their products. 

March 9 Merck and Schering-Plough announce a merger, making the combined company one of the largest pharmaceutical companies in the world. Merck pays 41.1 billion for the smaller company. 

As of April 2009, the membership has consisted of ten multinational pharmaceutical corporations (AZ, Boehringer Mannheim, GSK, Johnson Johnson, Lilly, Merck, Novartis, Pfizer, Schering-Plough, and Wyeth), and two technology/suppler organizations (Codexis and DSM). 

Schering-Plough, AKZO (Organon), Hofmann LaRoche (Syntex), Merck, American Home Products (Wyeth), etc. Penicillins/cephalosporins Eh Lilly, Glaxo-Smith-Kline (Beecham),... 

Bristol-Myers-Squibb, Pfizer, Shionogi, Fujisawa, Takeda, Aventis (Roussel/Hoechst), Merck, Novartis (Ciba), etc. Aminoglycosides Meiji, Eli Lilly, Schering-Plough, Pfizer,... 

Munobal (Hoechst) Prevex (Schering-Plough) Plendil (Astra Merck)... 

But they weren t. They were actually ads for an arthritis medicine (Celebrex, comarketed by Pfizer and Pharmacia), an allergy medicine (Schering-Plough s Clarinex), a different arthritis and pain medicine (Merck s Vioxx), a drug corn-... 

Figure 2 Sum of annual R D spending by six large pharmaceutical companies in the United States Pfizer, Merck, Eli Lilly, Bristol-Myers Squibb, American Home Products (renamed Wyeth in 2002), and Schering-Plough. These companies are listed in descending order of the total amount of their profit spent on R D. In terms of R D investment in 2000 as of percentage of sales that year, the order of the companies changes to Eli Lilly (19%), Pfizer (15%), Schering-Plough (14%), American Home Products (13%), Bristol-Myers Squibb (11%), and Merck (6%). On average, these companies spent almost 12% of their 2000 sales on R D. Data from Ref. 8.

---